Evaluation of incidence, significance, and prognostic role of circulating tumor microemboli and transforming growth factor-β receptor I in head and neck cancer

Head & Neck ◽  
2017 ◽  
Vol 39 (11) ◽  
pp. 2283-2292 ◽  
Author(s):  
Marcello Ferretti Fanelli ◽  
Thiago Bueno Oliveira ◽  
Alexcia Camila Braun ◽  
Marcelo Corassa ◽  
Emne Ali Abdallah ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Growth Factor ◽  
Head And Neck ◽  
Neck Cancer ◽  
Transforming Growth Factor ◽  
Transforming Growth Factor Β ◽  
Prognostic Role ◽  
Β Receptor ◽  
Circulating Tumor Microemboli

scholarly journals Attenuated Transforming Growth Factor β Signaling Promotes Nuclear Factor-κB Activation in Head and Neck Cancer

2009 ◽  
Vol 69 (8) ◽  
pp. 3415-3424 ◽  
Author(s):  
Jonah Cohen ◽  
Zhong Chen ◽  
Shi-Long Lu ◽  
Xin Ping Yang ◽  
Pattatheyil Arun ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Growth Factor ◽  
Head And Neck ◽  
Neck Cancer ◽  
Transforming Growth Factor ◽  
Transforming Growth Factor Β ◽  
Nuclear Factor Κb ◽  
Nuclear Factor

scholarly journals Circulating MicroRNAs as Prognostic Molecular Biomarkers in Human Head and Neck Cancer: A Systematic Review and Meta-Analysis

2019 ◽  
Vol 2019 ◽  
pp. 1-12 ◽  
Author(s):  
Shree Ram Lamichhane ◽  
Thanuja Thachil ◽  
Harriet Gee ◽  
Natalie Milic
Keyword(s):  
Systematic Review ◽  
Overall Survival ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Cancer Patients ◽  
Neck Cancer ◽  
Meta Analysis ◽  
Prognostic Role ◽  
Circulating Micrornas

Background. Circulating microRNAs (miRNAs) are potential molecular biomarkers for cancer detection; however, little is known about their prognostic role in head and neck cancer. This current study is aimed at evaluating the role of novel miRNAs in the survival of head and neck cancer patients. Materials and Methods. We performed a systematic literature search using online databases for articles published between December 2006 and February 2019. A meta-analysis was conducted to assess the correlation between miRNA expressions and overall survival (OS) among the selected head and neck cancer studies. After multilevel screening by reviewers, meta-analysis was performed using hazard ratios (HR) and associated 95% confidence interval (CI) of survival to calculate a pooled effect size. Result. A total of 1577 patients across 13 studies were included in the literature review, with 18 miRNAs upregulated and 4 miRNAs downregulated predicting a poor overall survival. The forest plot generated using cumulated survival data resulted in a pooled HR value of 2.943 (95% CI: 2.394-3.618) indicating a strong association of dysregulated miRNA expression with a poor outcome. Only 2 miRNAs—low levels of miR-9 and high levels of miR-483-5p—were observed in two studies, both showing a significant association with overall cancer survival. Conclusion. To our knowledge, this is the first comprehensive systematic review and meta-analysis that examines the prognostic role of circulating miRNAs from blood in head and neck cancer patients. The combined effect estimates a HR across multiple studies and also supports the previous individual findings that an alteration in miRNA expression is highly associated with poor prognosis. This has the potential to use serum and/or plasma miRNAs as biomarkers and become novel tools for predicting the prognosis of head and neck cancer patients in the near future.

Novel inactivating mutations of transforming growth factor-? type I receptor gene in head-and-neck cancer metastases

2001 ◽  
Vol 93 (5) ◽  
pp. 653-661 ◽  
Author(s):  
Taiping Chen ◽  
Wu Yan ◽  
Rebecca G. Wells ◽  
David L. Rimm ◽  
Jennifer McNiff ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Growth Factor ◽  
Head And Neck ◽  
Neck Cancer ◽  
Transforming Growth Factor ◽  
Receptor Gene ◽  
Type I ◽  
Cancer Metastases ◽  
Factor Type ◽  
Inactivating Mutations

scholarly journals EP-1070: Prognostic role of FDG-PET performed before or during radiotherapy in head and neck cancer

2016 ◽  
Vol 119 ◽  
pp. S515
Author(s):  
M. Min ◽  
P. Lin ◽  
M. Lee ◽  
I. Ho Shon ◽  
M. Lin ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Fdg Pet ◽  
Prognostic Role

scholarly journals TGF-Beta-Activated Cancer-Associated Fibroblasts Limit Cetuximab Efficacy in Preclinical Models of Head and Neck Cancer

Cancers ◽  
2020 ◽  
Vol 12 (2) ◽  
pp. 339 ◽  
Author(s):  
Ksenia M. Yegodayev ◽  
Ofra Novoplansky ◽  
Artemiy Golden ◽  
Manu Prasad ◽  
Liron Levin ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Growth Factor ◽  
Head And Neck ◽  
Neck Cancer ◽  
Stromal Cells ◽  
Transforming Growth Factor ◽  
Histopathological Analysis ◽  
Cancer Associated Fibroblasts ◽  
Tgf Beta ◽  
Stromal Compartment

Most head and neck cancer (HNC) patients are resistant to cetuximab, an antibody against the epidermal growth factor receptor. Such therapy resistance is known to be mediated, in part, by stromal cells surrounding the tumor cells; however, the mechanisms underlying such a resistance phenotype remain unclear. To identify the mechanisms of cetuximab resistance in an unbiased manner, RNA-sequencing (RNA-seq) of HNC patient-derived xenografts (PDXs) was performed. Comparing the gene expression of HNC-PDXs before and after treatment with cetuximab indicated that the transforming growth factor-beta (TGF-beta) signaling pathway was upregulated in the stromal cells of PDXs that progressed on cetuximab treatment (CetuximabProg-PDX). However, in PDXs that were extremely sensitive to cetuximab (CetuximabSen-PDX), the TGF-beta pathway was downregulated in the stromal compartment. Histopathological analysis of PDXs showed that TGF-beta-activation was detected in cancer-associated fibroblasts (CAFs) of CetuximabProg-PDX. These TGF-beta-activated CAFs were sufficient to limit cetuximab efficacy in vitro and in vivo. Moreover, blocking the TGF-beta pathway using the SMAD3 inhibitor, SIS3, enhanced cetuximab efficacy and prevented the progression of CetuximabProg-PDX. Altogether, our findings indicate that TGF-beta-activated CAFs play a role in limiting cetuximab efficacy in HNC.

scholarly journals Prognostic Role of p16 in Non-oropharyngeal Head and Neck Cancer

2018 ◽  
Vol 100 (5) ◽  
pp. 1319
Author(s):  
A.K. Bryant ◽  
L. Vitzthum ◽  
K. Zakeri ◽  
H. Shen ◽  
J.D. Murphy ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Prognostic Role
Sign in / Sign up

Export Citation Format

Share Document